In addition, studies have been undertaken to carry out genomic analyses to predict survival or treatment response in mutated BRAF melanoma, but these studies all used tumour tissue and, in most cases, few samples were taken, due to the risks involved in rebiopsy, among other considerations [26]. This evidence concerns the gene BRAF and neoplasm.